ContherVa™ - Conductive Thermal Vaginal Treatment
The Most Convenient Thermal Therapy For Women’s Health
What is ContherVa™
A New Industry Gold Standard
ContherVa™ is a revolutionary, non-invasive thermal therapy designed for women experiencing health challanges as Vulvovaginal Atrophy (VVA) and Genitourinary Syndrome of Menopause (GSM). Utilizing conductive heat distribution therapy (COHD™ Technology), it restores vaginal tissue health, enhances natural lubrication, and improves elasticity, offering a safe and effective alternative to traditional treatments.
Key Benefits
New Technology & Treatment for Women's Health
Setting a new gold standard in the industry with a non-hormonal, non-invasive office-based solution.
-
360° Full Contact with the entire Vaginal Wall Length
Comprehensive coverage ensuring homogeneous heating patterna long the entire treatment area for optimalclinical results. -
No Downtime, optimal comfort convenience
Immediate return to daily activities. -
Anatomically Adaptive Applicator
Features an adjustable applicator designed to adapt precisely to each woman's unique anatomical structure, enabling personalized and optimized treatment. -
Women's privacy
Women experience a truly relaxed and private treatment, ensuring a more comfortable, less embarrassing experience. -
Hands-Free Operation
Enables medical staff to prioritize patient comfort and care, while enhancing overall clinic efficiency. -
Disposable Applicator
Each treatment session utilizes a hygienic disposable applicator, promoting safety and sanitation.
What is COHD™ Technology
COHD™ Conductive Heat Distribution
COHD™ technology utilizes non-ablative thermal energy for conductive heat transfer to the target area. The ContherVa™ applicator is placed in the vagina and heated by controlled liquid circulation, up to 45°C verified by double temperature monitoring, ensuring safe treatment, stimulation of the target tissue, and maximal convenience.
Clinical Evidence
In a clinical study evaluating the feasibility and safety of ContherVa™ vaginal applicator in female patients suffering from Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS), the results show that ContherVa™ improves the symptoms of IC/BPS during the treatment course and at 1 and 3-month follow ups with a high safety profile.
About Us
Surogel Ltd. is dedicated to commercializing overlooked technological innovations.
Our mission is to empower these promising innovations by establishing robust manufacturing methods, and crafting comprehensive go-to-market strategies, leading them to the success they deserve.
Surogel Ltd. is driven by a passion for innovation and a drive to redefine industrystandards.
